Slides: Integrating EPA based therapy in the management of residual CV risk
Slides as educational service to PACE members and meeting participants.
This lecture by Prof. Ph. Gabriel Steg was part of a EBAC-accredited symposium "Tackling residual risk beyond LDL-c therapy: The emerging role of EPA & triglycerides" held during ESC Congress 2021.
The content is aimed for medical professionals. To view this item member registration is needed. Register for free to get unlimited access to our educational resources.
Share this page with your colleagues and friends: